Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis by Wagschal, Alexandre et al.
Genome-wide identification of
microRNAs regulating cholesterol
and triglyceride homeostasis
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Wagschal, Alexandre, S Hani Najafi-Shoushtari, Lifeng Wang,
Leigh Goedeke, Sumita Sinha, Andrew S deLemos, Josh C Black,
et al. 2015. Genome-Wide Identification of microRNAs Regulating
Cholesterol and Triglyceride Homeostasis. Nature Medicine 21, no.
11: 1290–1297. doi:10.1038/nm.3980.
Published Version doi:10.1038/nm.3980
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:30510306
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
Genome-wide identification of microRNAs regulating cholesterol 
and triglyceride homeostasis
Alexandre Wagschal1,2, S Hani Najafi-Shoushtari1,2,17, Lifeng Wang1,2, Leigh Goedeke3, 
Sumita Sinha4, Andrew S deLemos5,17, Josh C Black1,6, Cristina M Ramírez3, Yingxia Li7, 
Ryan Tewhey8,9, Ida Hatoum10, Naisha Shah11, Yong Lu11, Fjoralba Kristo1, Nikolaos 
Psychogios4, Vladimir Vrbanac12, Yi-Chien Lu13, Timothy Hla13, Rafael de Cabo14, John S 
Tsang11, Eric Schadt15, Pardis C Sabeti8,9, Sekar Kathiresan4,6,8,16, David E Cohen7, 
Johnathan Whetstine1,6, Raymond T Chung5,6, Carlos Fernández-Hernando3, Lee M 
Kaplan6,10, Andre Bernards1,6,16, Robert E Gerszten4,6, and Anders M Näär1,2
1Massachusetts General Hospital Center for Cancer Research, Charlestown, Massachusetts, 
USA
2Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA
3Section of Comparative Medicine, Department of Pathology, Yale University School of Medicine, 
New Haven, Connecticut, USA
4Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, 
Boston, Massachusetts, USA
5Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical 
School, Boston, Massachusetts, USA
6Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 
Charlestown, Massachusetts, USA
7Department of Medicine, Division of Gastroenterology, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, Massachusetts, USA
Correspondence should be addressed to A.M.N. naar@helix.mgh.harvard.edu).
17Present addresses: Department of Cell and Developmental Biology, Weill Cornell Medical College, Cornell University, New York, 
NY, USA and Research Department, Weill Cornell Medical College in Qatar, Qatar Foundation, Doha, Qatar (S.H.N.-S.); Hepatology 
and Transplant Center, Carolinas Medical Center, Charlotte, North Carolina, USA (A.S.D.).
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: details are available in the online version of the paper.
Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
AUTHOR CONTRIBUTIONS
S.H.N.-S. and A.M.N. conceived and carried out the initial miR-128-1 studies that provided support for the expanded project. A.W. 
and A.M.N. conceived and designed the expanded, published studies, interpreted the data, and wrote the manuscript, which was 
commented on by all authors. A.W., S.H.N.-S., L.W., S.S., Y. Li, F.K., N.P., D.E.C. and R.E.G. performed experiments and analyzed 
data in Apoe deficient mice and in C57BL/6 mice. L.G., C.M.R. and C.F.-H. quantified miRNAs in Rhesus monkeys and mice fed 
with different diets and performed efflux experiments in mouse peritoneal macrophages. N.S., Y. Lu, J.S.T., E.S., R.T., I.H., P.C.S. and 
L.M.K. contributed to the human liver miR-QTL analysis. Y.-C.L. and T.H. performed the Ago2 PAR-CLIP analysis in BMDMs. 
A.S.d. and R.T.C. performed the liver histology analysis. V.V. injected the lentivirus in C57BL/6 mice. J.C.B. and J.W. performed 
DNA microarray analysis from mouse liver samples prepared by A.W. S.K. and A.B. analyzed the GWAS data. R.d.C. carried out the 
non-human primate studies.
HHS Public Access
Author manuscript
Nat Med. Author manuscript; available in PMC 2016 August 22.
Published in final edited form as:
Nat Med. 2015 November ; 21(11): 1290–1297. doi:10.1038/nm.3980.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
8Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, 
Massachusetts, USA
9Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, 
Massachusetts, USA
10Obesity, Metabolism and Nutrition Institute and Gastrointestinal Unit, Massachusetts General 
Hospital, Harvard Medical School, Boston, Massachusetts, USA
11Systems Genomics and Bioinformatics Unit, Laboratory of Systems Biology, National Institute of 
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
12Harvard University Center for AIDS Research, Cambridge, Massachusetts USA
13Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell 
Medical College, Cornell University, New York, New York, USA
14Experimental Gerontology Section, Translational Gerontology Branch, National Institute on 
Aging, National Institutes of Health, Baltimore, Maryland, USA
15Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New 
York, New York, USA
16Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, 
USA
Abstract
Genome-wide association studies (GWASs) have linked genes to various pathological traits. 
However, the potential contribution of regulatory noncoding RNAs, such as microRNAs 
(miRNAs), to a genetic predisposition to pathological conditions has remained unclear. We 
leveraged GWAS meta-analysis data from >188,000 individuals to identify 69 miRNAs in physical 
proximity to single-nucleotide polymorphisms (SNPs) associated with abnormal levels of 
circulating lipids. Several of these miRNAs (miR-128-1, miR-148a, miR-130b, and miR-301b) 
control the expression of key proteins involved in cholesterol-lipoprotein trafficking, such as the 
low-density lipoprotein (LDL) receptor (LDLR) and the ATP-binding cassette A1 (ABCA1) 
cholesterol transporter. Consistent with human liver expression data and genetic links to abnormal 
blood lipid levels, overexpression and antisense targeting of miR-128-1 or miR-148a in high-fat 
diet–fed C57BL/6J and Apoe-null mice resulted in altered hepatic expression of proteins involved 
in lipid trafficking and metabolism, and in modulated levels of circulating lipoprotein-cholesterol 
and triglycerides. Taken together, these findings support the notion that altered expression of 
miRNAs may contribute to abnormal blood lipid levels, predisposing individuals to human 
cardiometabolic disorders.
GWASs have been extensively used to identify common variants, termed SNPs, associated 
with various human traits. Most of these studies have focused on genes in proximity 
(typically within 100 kb) to SNPs as potential causative links to traits. However, protein-
coding genes account for only a very small proportion of the transcribed human genome, 
thus highlighting a lack of understanding of the possible contributions of noncoding RNAs 
to human traits and disease. Aberrant cholesterol and lipid homeostasis, as well as altered 
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energy metabolism, are implicated in cardiometabolic diseases such as metabolic syndrome, 
type 2 diabetes, and coronary artery disease (CAD)1. Despite progress in the treatment (for 
example, with statins) of abnormal levels of cholesterol and other lipids, cardiometabolic 
diseases represent prominent causes of human morbidity and mortality2, thereby 
emphasizing the need for new therapeutic strategies. miRNAs, comprising a class of short 
(20–24 nt) regulatory RNAs that modulate mRNA translation and turnover, have recently 
emerged as crucial regulators of cholesterol, triglycerides (TAG), glucose and energy 
homeostasis3,4. We and others recently identified the miR-33 family of miRNAs as central 
regulators of mammalian cholesterol and lipid metabolism5–9. Several additional miRNAs 
have also been found to control aspects of cellular and in vivo cholesterol and lipid 
homeostasis4,10. However, the potential contribution in humans of miRNAs to derangements 
in circulating cholesterol and lipid levels, and to associated cardiometabolic disease, has 
remained unclear.
RESULTS
MicroRNAs are linked to SNPs associated with abnormal blood lipids
To explore whether miRNAs might be functionally linked to human genetic predispositions 
to abnormalities in circulating levels of cholesterol and (other) lipids, we carried out a 
systematic analysis of data from GWASs, involving >188,000 individuals, that associated 
common SNPs with plasma lipid levels11. We annotated these results to determine whether 
sequences encoding miRNAs might be located in proximity (<100 kb) to SNPs linked to 
aberrant lipid levels11. Our analysis identified 69 miRNAs in the vicinity of SNPs with 
genome-wide significant (P < 5 × 10−8) association with abnormal levels of total cholesterol 
(TC), HDL cholesterol (HDL-C), LDL-C, or TAGs (Supplementary Table 1). In several 
cases, these genomic loci harbor a nearby protein-coding gene that probably represents the 
main contributor to the link between the SNP and aberrant blood lipid levels (for example, 
fatty acid desaturases 1–3 (FADS1–FADS3) on chromosome 11 are associated with altered 
levels of all four blood lipid categories, and cholesteryl ester transfer protein (CETP) on 
chromosome 16 is associated with altered levels of HDL-C)12,13. However, many of the loci 
do not contain an obvious candidate gene.
We reasoned that miRNAs causally linked with abnormal blood lipids would be predicted to 
target genes associated with cholesterol and lipid or metabolic homeostasis, and/or with 
cardiometabolic disorders. We first extracted lists of predicted conserved targets for the 69 
miRNAs from the widely used TargetScan 6.2 website14. We then analyzed these predicted 
targets using the DAVID gene ontology (GO) program15, filtered for statistically significant 
links with cardiometabolic disorders such as type 2 diabetes, obesity and atherosclerosis (see 
Online Methods). From these analyses, the top miRNAs with predicted mRNA targets 
involved in metabolism and metabolic control, and with significant association with 
cardiometabolic disorders in GO analysis, were miR-128-1 (near SNPs associated with 
altered TC and LDL-C levels), miR-148a (TC, LDL-C, and TAGs), and the physically 
closely linked and sequence-related (sharing seed sequence) miR-130b and miR-301b (TC 
and HDL-C) (Fig. 1a–c and Supplementary Tables 2–4). Notably, the genomic loci 
harboring these four miRNAs do not have clear candidate genes that might account for the 
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genetic association of these loci with abnormal blood lipid levels. We therefore focused our 
follow-up studies on these miRNAs as candidate noncoding RNAs contributing to the blood 
lipid associations identified in GWASs.
miR-128-1 is located in intron 18 of R3HDM1, a gene on human chromosome 2 with 
unknown function; miR-148a is located in a gene-poor intergenic region of human 
chromosome 7; and miR-130b and miR-301b are found in close proximity in an inter-genic 
region near the UBE2L3 gene on human chromosome 22 (Fig. 1a–c). The four miRNAs are 
highly conserved among vertebrates (data not shown) and all four miRNAs are expressed in 
a number of human tissues (Supplementary Fig. 1). miR-128-1 appears to be extensively co-
expressed with its host gene R3HDM1 (suggesting that they share the same primary 
transcript), and miR-148a is predominantly expressed in liver. Notably, the expression of 
miR-148a and miR-130b was significantly increased in the liver of high-fat diet (HFD)-fed 
mice and rhesus macaques, suggesting a potential evolutionarily conserved link to metabolic 
regulatory function (Supplementary Fig. 2).
Most of the SNPs in our analysis are located in noncoding intergenic or intronic regions, a 
number of which exhibit hallmarks of enhancers and open chromatin architecture (for 
example, DNase I hypersensitivity; Supplementary Table 3), suggesting that some of these 
SNPs may alter regulatory DNA sequence elements controlling miRNA expression. To 
explore whether SNPs located near the four miRNAs are associated in cis with miRNA 
expression, we performed miRNA expression quantitative trait locus (miR-QTL) analysis 
using 424 liver samples from gastric bypass surgery patients (clinical information is 
available in Online Methods). Our analysis revealed a number of potential cis miR-QTLs 
(Fig. 1d,e; Supplementary Figs. 3 and 4; Supplementary Table 5), including ones near the 
miR-128-1 locus that broadly overlap with the GWAS TC SNP region (Fig. 1d), and to a 
lesser extent, the LDL-C SNP region (Supplementary Fig. 3a). In addition, there appears to 
be a discrete miR-QTL peak near the CXCR4 gene in this locus that is nearby an apparent 
enhancer, which has been shown to be bound by multiple immune cell–associated 
transcription factors (for example, PU.1, EBF, PBX3, IRF4; chromatin immunoprecipitation 
data are referenced in the University of California, Santa Cruz (UCSC) Genome Browser). 
We speculate that this signal may represent a contribution from immune and/or 
inflammatory cell infiltration into the liver in the morbidly obese patient population from 
which the liver samples were taken (Fig. 1d and Supplementary Fig. 3); however, this 
hypothesis would need to be further tested. There is also a strong miR-QTL peak near 
miR-148a that includes two SNPs (rs4722551 and rs4719841) in the promoter region of 
miR-148a (Fig. 1e; Supplementary Fig. 3b,c and Supplementary Table 5); these two SNPs 
are associated with TC, TAGs and LDL-C levels (Supplementary Table 3). There was no 
apparent overlap between liver miR-QTLs in the miR-130b and miR-301b locus and the 
SNPs identified by GWAS (Supplementary Fig. 4 and data not shown), suggesting either that 
liver is not a relevant tissue for such an association, or that the expression of these miRNAs 
is not linked with the GWAS SNPs in this cohort of obese individuals. Taken together, the 
results of this miR-QTL analysis underscore the potential of GWASs to identify genomic 
variants linking miRNA expression to human phenotypes.
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MicroRNA regulation of lipid-related genes and cholesterol and lipoprotein trafficking
All four miRNAs are predicted to target key regulators of lipid homeostasis and lipoprotein 
trafficking, including the LDLR, which is important for hepatic clearance of LDL 
cholesterol from the circulation16,17, as well as the ATP-binding cassette transporter A1 
(ABCA1), which is crucial for HDL biogenesis, cholesterol efflux from peripheral cells such 
as atherogenic macrophages, and reverse cholesterol transport (RCT)18–20 (Supplementary 
Table 4). In accordance with these target predictions, introduction of miR-128-1, miR-148a, 
miR-130b and miR-301b precursor oligonucleotides into human liver-derived (HepG2 
hepatoma) cells decreased LDLR and ABCA1 levels, compared to precursor control-
transfected cells. Conversely, transfection of antimiR oligonucleotides increased LDLR and 
ABCA1 levels compared to mock-treated cells (Fig. 2). The results of the antimiR 
experiments show that endogenous miRNAs act to repress LDLR and ABCA1 expression in 
HepG2 cells. These miRNAs are also predicted to target other essential factors involved in 
lipid and glucose homeostasis (Supplementary Table 4). We confirmed that miR-128-1 
regulates expression of the insulin receptor (InsR) and the insulin receptor substrate 1 
(IRS1), which acts downstream of the insulin receptor in the insulin signaling pathway21, as 
well as expression of SIRT1, a NAD+-dependent energy sensor and lysine deacetylase22 
(Fig. 2a). Notably, of these four miRNAs, three (miR-148a, miR-130b and miR-301b) 
control expression of salt-inducible kinase 1 (SIK1), a regulator of hepatic lipogenesis that 
inhibits SREBP-1c activity by direct phosphorylation23, as well as expression of several 
components of the heterotrimeric AMP-activated protein kinase (AMPK; PRKAA1 and 
PRKAA2), a key energy stress sensor and regulator24 (Fig. 2b–d). Moreover, miR-148a 
regulates expression of carnitine palmitoyltransferase 1 (CPT1A), a central regulator of 
mitochondrial fatty acid β-oxidation25 (Fig. 2b), whereas miR-130b controls expression of 
PPAR gamma coactivator 1 alpha (PGC1-α), a transcriptional coactivator, and insulin 
induced gene 1 (INSIG1), which controls the activity of SREBPs and HMG-CoA 
reductase26 (Fig. 2c). Altogether, our data suggest that these miRNAs may control multiple 
metabolic regulatory circuits that act in concert, which could result in cumulative effects on 
metabolic output.
LDL-C uptake by the LDLR in the liver is an essential physiological process regulating 
circulating levels of LDL-C16. This process is of clinical importance because of the 
prominent role of LDLR-dependent hepatic clearance of circulating LDL-C in preventing 
atherosclerosis and cardiovascular disease17. Indeed, elevated hepatic LDLR expression is a 
key anti-atherosclerotic effect of statins27, and mutations in the LDLR gene can cause 
familial hypercholesterolemia (FH), a severe disease characterized by high levels of 
circulating LDL-C and premature death owing to accelerated cardiovascular disease28. 
Because of the physiological and clinical importance of the LDLR in regulating circulating 
LDL-C, and as LDLR expression has not been previously shown to be under miRNA 
control, we wished to further verify the functional effects of the four miRNAs on LDLR 
expression and LDL-C uptake. First, we examined whether miR-128-1, miR-148a, 
miR-130b, and miR-301b regulate LDLR expression directly through its 3′ untranslated 
region (UTR), which possesses predicted target sequences for these miRNAs (TargetScan 
6.2). The 3′ UTR of the human LDLR gene, when fused to the 3′ end of a firefly luciferase 
reporter, resulted in decreased luciferase activity in HEK293T cells (Fig. 2e) as compared to 
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cells transfected with an empty vector, indicating the presence of repressive elements within 
the LDLR 3′ UTR. Transfection of miRNA precursors caused further repression, whereas 
mutation of the predicted miRNA target sites in the LDLR 3′ UTR abolished the effects of 
the four miRNAs (Fig. 2f). Next, we evaluated whether the four miRNAs modulate LDL-C 
uptake into human hepatoma cells. Indeed, internalization of fluorescently labeled LDL-C 
(Dil-LDL) into HepG2 cells was strongly decreased upon transfection of miR-128-1, 
miR-148a, miR-130b, and miR-301b as compared to cells transfected with precursor 
control. Conversely, transfection of antisense oligonucleotides directed against these 
miRNAs caused a significant increase in Dil-LDL uptake, as compared to scrambled control 
antimiR-treated cells (Fig. 2g,h). Together, these findings demonstrate miRNA repression of 
the LDLR through its 3′ UTR, with functional effects on LDL-C uptake into liver-derived 
cells.
ABCA1 is a critical component of the RCT pathway responsible for removing cholesterol 
from peripheral cells (for example, atherogenic macrophages) and transporting it back to the 
liver for excretion18. In particular, ABCA1 facilitates the production of nascent lipid-poor 
HDL in the liver and intestines, and it acts in peripheral cells and tissues to pump out 
cholesterol that can then be ferried by HDL back to the liver. Similarly to the 3′ UTR of 
LDLR, we found that the 3′ UTR of ABCA1 was directly targeted by miR-128-1, 
miR-148a, miR-130b, and miR-301b, as revealed by miRNA overexpression and the 
introduction of point mutations into the miRNA target sites in the ABCA1 3′ UTR in the 
luciferase fusion assay (Fig. 3). Previous studies have shown that miRNAs such as miR-33a 
and miR-33b control ABCA1 levels and cholesterol efflux in liver cells and in macrophages, 
a cell type with direct relevance to atherosclerosis5–9. We found that all four miRNAs 
identified in the GWAS analysis were similarly able to modulate expression of ABCA1 in 
the human HepG2 liver cell line and in the mouse macrophage cell line J774 (Fig. 2a–d and 
Fig. 3c), as well as in peritoneal macrophages isolated from C57BL/6 mice, which were 
treated with an LXR agonist (T090) to further activate expression of Abca1 (Fig. 3e). 
Accordingly, miR-128-1, miR-148a, miR-130b, and miR-301b significantly affected the 
cholesterol efflux capacity of these cells (Fig. 2i,j and Fig. 3d,f). Ago2 PAR-CLIP analysis29 
in mouse bone marrow–derived macrophages independently identified all four miRNAs as 
regulators of two distinct sites in the 3′ UTR of Abca1 mRNA (Fig. 3g). Taken together, our 
data indicate that miR-128-1, miR-148a, miR-130b, and miR-301b control expression of 
both LDLR and ABCA1 in functionally relevant cell types, with effects on cholesterol 
trafficking.
miRNA overexpression in mice inhibits hepatic Ldlr and Abca1 expression and modulates 
circulating cholesterol-lipoprotein levels
On the basis of the miR-QTL data linking SNPs associated with abnormal blood lipid levels 
to miR-128-1 and miR-148a expression, we chose to study the effects of these miRNAs on 
circulating blood lipids in vivo. We first investigated the effects of miR-128-1 and miR-148a 
overexpression in C57BL/6J mice fed an HFD (60% calories as fat). Mice were injected in 
the tail vein with lentivirus expressing pre-miR-128-1 or pre-miR-148a, or were injected 
with a control virus, and then serum and liver were harvested after two weeks. The miRNA-
expressing viruses, which also encoded GFP, were active in liver, as assessed by GFP 
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expression (Fig. 4). In accordance with the in vitro findings, miR-128-1 and miR-148a 
overexpression strongly reduced hepatic levels of Abca1 and Ldlr compared with control 
scrambled pre-miRNA expression, and it also altered the expression of other targets such as 
Irs1 (miR-128-1) and Cpt1a (miR-148a) (Fig. 4a,d–h and data not shown). The circulating 
cholesterol and lipid profile of mice overexpressing miR-148a and miR-128-1 revealed a 
marked reduction in plasma HDL-C levels compared with controls, as expected from the 
requirement of Abca1 for HDL formation18–20 (Fig. 4b,c).
To evaluate the consequence of inhibition of endogenous miR-128-1 and miR-148a on LDL 
clearance, we injected locked nucleic acid (LNA) antisense oligonucleotides (antimiRs) into 
C57BL/6J mice, followed by retro-orbital injection of fluorescently labeled LDL (Dil-LDL), 
and assessed clearance of LDL in blood over the subsequent 5 h. AntimiR-128-1– and 
antimiR-148a–treated mice exhibited increased LDL clearance in comparison with controls 
(Fig. 4i,j), in keeping with elevated hepatic Ldlr expression and increased hepatic Dil-LDL 
levels (Supplementary Fig. 5).
Antisense inhibition of miR-128-1 and miR-148a in Apoe−/− mice alters cholesterol and 
metabolism
Next, we investigated the effects of antimiR-128-1 and antimiR-148a treatment in Apoe−/− 
mice fed a Western-type diet. Apoe−/− mice recapitulate some aspects of the abnormal serum 
lipid profiles observed in humans with dyslipidemia (for example, high VLDL-C and LDL-
C levels and low HDL-C levels), and they exhibit accelerated atherosclerosis when fed a 
Western-type diet30,31. Short-term studies (5 d) with tail vein injection of 20 mg/kg 
antimiR-128-1, antimiR-148a, or control nonspecific LNA antimiR on days 1 and 3, 
revealed strongly decreased hepatic miR-128-1 and miR-148a levels, indicating potent on-
target effects of both the miR-128-1– and miR-148a– targeting antimiRs (Figs. 5 and 6). As 
miR-128-1 exhibits some sequence similarity with the miR-27 family and shares a number 
of targets with those miRNAs, we verified that antimiR-128-1 LNA did not affect hepatic 
miR-27 levels (Supplementary Fig. 6a). In accordance with the in vitro studies and in vivo 
data in C57BL/6J mice, antisense inhibition of miR-128-1 and miR-148a increased hepatic 
levels of Ldlr as compared with control LNA-treated mice (Figs. 5b and 6b). AntimiR-148a 
treatment also markedly elevated hepatic Abca1 levels at both the mRNA and protein levels 
(Fig. 5b,c). Although we did not observe consistent effects of antimiR-128-1 treatment on 
Abca1 expression across the treated animals in the short-term study (data not shown), we 
found potent de-repression of other targets such as the insulin signaling components Irs1 and 
the insulin receptor (Insr), with a concomitant increase in insulin signaling output, as 
evidenced by elevated phosphorylated Akt (Fig. 6b). These results suggest that abnormal 
expression of miR-128-1 might contribute to insulin resistance, a hallmark of the metabolic 
syndrome1, as well as to other effects of insulin dysregulation, such as hepatic steatosis and 
dyslipidemia.
The circulating cholesterol and lipid profile of Apoe−/− mice treated with antimiR-148a 
revealed an increase of HDL-C levels, as expected from the involvement of ABCA1 in 
HDL-C generation as compared to controls, but little effect on VLDL-associated TAGs (Fig. 
5d,f and Supplementary Fig. 6b). Interestingly, we also observed a decrease in LDL-C levels 
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after inhibition of miR-148a in Apoe−/− mice (Fig. 5d,e). In this context, because in mice 
ApoE function is required for LDL-C clearance via LDLR, the decrease in circulating LDL-
C levels observed after inhibition of miR-148a must result from LDLR-independent 
processes. AntimiR-128-1–treated Apoe−/− mice exhibited modestly decreased blood levels 
of VLDL-C and LDL-C and a shift of HDL-C to a smaller and denser form, presumably 
nascent HDL-C (Supplementary Fig. 6c). The miRNA-targeting LNA injections did not 
cause liver toxicity, as assessed by blood levels of alanine transaminase (ALT) and 
asparagine transaminase (AST) (Supplementary Fig. 6d,e). Together, these findings show 
that miR-148a and miR-128-1, which are located in genomic regions harboring SNPs 
associated with abnormal blood lipid levels, regulate circulating lipoprotein-cholesterol 
levels in vivo in an experimental model of metabolic disease, probably through multiple 
mechanisms acting in concert (for example, regulation of cholesterol and lipid transporters, 
hepatic insulin signaling, and cholesterol and TAG production and clearance).
To further test the ability of miR-128-1 and miR-148a to regulate lipid metabolism, as well 
as the ability of miR-128-1 to affect glucose homeostasis and insulin sensitivity, we carried 
out longitudinal studies (16 weeks) using once-weekly subcutaneous injection of 
antimiR-128-1, antimiR-148a (each 20 mg/kg) or control scrambled LNA oligonucleotide in 
Apoe−/− mice fed a Western-type diet. Long-term antisense antagonism of miR-148a 
maintained the strong elevation of HDL-C levels seen in the short-term study, whereas the 
LDL-C–lowering effect found in the short-term treatment was no longer apparent (Fig. 5g–
i). In antimiR-128-1–treated animals, we found strongly decreased circulating total 
cholesterol levels (~35%), reflected primarily in a reduction of VLDL-C/LDL-C, as well as 
a marked decrease in VLDL-associated TAGs (~25%), as compared with control LNA-
injected mice (Fig. 6c,d). Gene expression analysis by DNA microarray profiling and 
quantitative RT-PCR analysis of livers from antimiR-128-1–treated mice showed that the 
mRNA levels of many predicted miR-128-1 targets (TargetScan 6.2 mouse), including Ldlr 
and Abca1, were significantly de-repressed (Supplementary Fig. 7a and Supplementary 
Table 6). Pathological examination of the livers, as assessed by H&E and Oil Red O 
staining, showed significantly (P < 0.05) decreased hepatic steatosis in animals treated with 
antimiR-128-1 (Fig. 6e and Supplementary Fig. 7c,d) as compared to controls. We speculate 
that this effect on steatosis may in part be due to decreased lipogenesis, as Fasn, a rate-
limiting enzyme in fatty acid biosynthesis, was downregulated (Supplementary Fig. 7a). 
AntimiR-128-1–treated mice also showed significantly improved glucose homeostasis and a 
modest effect on insulin sensitivity, as revealed by intra-peritoneal glucose tolerance test (IP-
GTT) and insulin tolerance test (ITT) (Fig. 6f and Supplementary Fig. 7b). The potent effect 
of antimiR-128-1 treatment on circulating cholesterol and TAGs in Apoe−/− mice cannot be 
explained by changes in hepatic Ldlr and Abca1 levels, but may relate to the decreased 
VLDL secretion that could accompany improved hepatic insulin sensitivity. Accordingly, we 
observed a modest but significant decrease in VLDL secretion and lowered circulating 
apoB-100 levels in Apoe−/− mice treated with antimiR-128-1 (Fig. 6g and Supplementary 
Fig. 8).
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DISCUSSION
Previous GWASs have uncovered associations of genes with various human traits; however, 
to our knowledge, no systematic analysis has been carried out to evaluate potential 
associations of regulatory noncoding RNAs, such as miRNAs, with such traits. We leveraged 
GWAS meta-analysis in >188,000 individuals to identify 69 miRNAs located in genomic 
regions associated with abnormal blood lipid levels. Our work identifies four miRNAs 
(miR-128-1, miR-148a, miR-130b and miR-301b) that regulate LDL-C uptake and 
cholesterol efflux by controlling the expression of the LDLR and ABCA1 proteins, 
respectively, in physiologically relevant cell types such as liver and macrophage-derived 
cells. miR-QTL studies using liver tissue from 424 morbidly obese individuals revealed an 
association of miR-128-1 and miR-148a expression with SNPs linked to abnormal human 
blood lipid levels, suggesting the relevance of these miRNAs, identified by GWASs, to 
human cardiometabolic disorders. In vivo studies in C57BL/6J mice and the Apoe−/− mouse 
metabolic disease model verified that miR-128-1 and miR-148a can indeed regulate 
cholesterol/lipid and energy homeostasis. Moreover, the effects of antimiR-128-1 treatment 
on TAGs, as well as on insulin signaling and sensitivity and glucose homeostasis, in Apoe−/− 
mice suggests that miR-128-1 dysregulation could potentially contribute to other aspects of 
the metabolic syndrome.
Taken together, our studies suggest that noncoding RNAs, such as miRNAs, uncovered in 
GWAS analyses could play key roles in contributing to human disease states. The 
therapeutic tractability of potent and specific antisense technologies targeting single or 
multiple miRNAs implicated in human cardiometabolic diseases may thus have important 
clinical ramifications for the treatment of these diseases.
ONLINE METHODS
Mouse lentivirus and antimiR studies
Lentivirus—Lentiviruses encoding miR-128-1 (miRZip-128-1) and miR-148a 
(miRZip-148a) precursors, as well as a scrambled control (miRZip-Scramble), were 
obtained from System Biosciences, Inc. (no. CS970MZ-Z). 12-week-old male C57BL/6J 
mice were purchased from the Jackson Laboratory, Bar Harbor, ME, and fed an HFD 
supplemented with 60% kcal from milk fat (D12492, Research Diets) during treatment. 
Mice were injected in the tail vein with 1 × 109 pfu/mouse diluted in 100 μl PBS on day 1, 
and serum and liver were harvested on day 14.
AntimiRs—LNA antimiRs directed against miR-128-1 (TTCACTGTG), miR-148a 
(TTCTGTAGTGCACTG), and a scrambled control LNA oligonucleotide (TCATACTA) 
were purchased from Exiqon, Denmark. Experiments were performed using 12-week-old 
male Apoe-null mice. Mice (no. 002052) were purchased from the Jackson Laboratory, Bar 
Harbor, ME and fed a Western-type diet supplemented with 45% kcal from milk fat 
(D12451, Research Diets) for 6 weeks before and during treatment. For the short-term (5 d) 
studies, miR-128-1 and miR-148a LNA antimiRs (20 mg/kg) or control scrambled LNA 
oligonucleotide were dissolved in PBS (total volume of 200 μl) and administered through 
tail vein injections on days 1 and 3 at the same time of day on each day of treatment. Mice 
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were sacrificed 48 h after the last tail vein injection. The longitudinal studies were 
performed in Apoe-null mice fed with a Western-type diet for 16 weeks, with once-weekly 
subcutaneous injection of the miR-128-1 or miR-148a LNA antimiRs (20 mg/kg) or control 
scrambled LNA oligonucleotide. Upon sacrifice, livers were collected and ~1 ml of blood 
was obtained from each mouse by right ventricular puncture. Blood was centrifuged at 8,000 
rpm for 5 min to obtain serum, which was frozen at −80 °C. Total serum cholesterol and 
triglyceride levels were determined with a Heska Dri-Chem 4000 Chemistry Analyzer 
(Heska, Loveland, CO) at Massachusetts General Hospital, Center for Comparative 
Medicine, Diagnostic Laboratory. FPLC analysis of pooled serum was carried out as 
described5. All mouse procedures were approved by the Massachusetts General Hospital 
Institutional Animal Care and Use Committee.
GWAS analysis
The GWAS analysis was performed by identifying miRNAs located in proximity (<100 kb) 
of SNPs (P-value <5 × 10−8) associated with total cholesterol (TC), low-density lipoprotein-
cholesterol (LDL-C), high- density lipoprotein-cholesterol (HDL-C) and triglyceride (TAG) 
levels11. The list of miRNAs was extracted from miRBase (release 19). The predicted target 
genes were extracted using the TargetScan (6.2, Human) and gene ontology/functional 
annotation was performed with the DAVID software based on two diseases categories: 
GENETIC_ASSOCIATION_DB_DISEASE (http://geneticassociationdb.nih.gov/) and 
OMIM_DISEASE (http://www.ncbi.nlm.nih.gov/omim). To represent the SNP (P-value 
<10−4) density in proximity of miRNAs shown in Figure 1, we extracted the list of SNPs 
associated with TC, LDL-C, HDL-C and TAG levels previously published by the Global 
Lipids Genetics Consortium11,32. The recombination values shown in Figure 1b–d were 
obtained as pre-calculated values from the 1000 Genomes consortium and were accessed 
from (http://mathgen.stats.ox.ac.uk/impute/
ALL_1000G_phase1integrated_feb2012_impute/). The R2 calculations were produced using 
Plink with the 1000 Genomes phase 1 variants for the EUR (CEU, TSI, FIN, GBR, IBS) 
populations.
miR-QTL analysis using a RYGB patient cohort
For this study, we were interested in finding cis QTLs for four miRNAs: miR-128-1 
(chromosome 2), miR-148a (chromosome 7), and the physically closely linked and related 
miR-130b and miR-301b (chromosome 22 – their seed sequences are identical). The full 
data set including QTL and expression analysis of all miRNAs and SNPs profiled will be 
published separately.
From February 2000 until April 2007, consent was obtained from 1,018 individuals 
undergoing Roux-en-Y gastric bypass (RYGB) at the Massachusetts General Hospital to 
collect and analyze tissue samples removed at the time of surgery. Surgical procedures and 
the study population have been described previously33–35. Briefly, intraoperative liver 
samples were collected in RNAlater (Ambion) and stored at −80 °C. Genomic DNA was 
extracted from liver samples, and 950 samples were successfully genotyped with the 
Illumina HumanHap 650Y BeadChip array at the Gene Expression Laboratory of Rosetta 
Inpharmatics. MicroRNAs were extracted from liver tissues and RT-PCR was performed to 
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derive miRNA expression from the samples using a previously published approach36. 
Standard curves were created for all miRNAs profiled, allowing for the characterization of 
miRNA abundance as copies/10 pg of total RNA, with a typical mammalian cell containing 
10–30 pg of total RNA. All human studies were approved by and conducted in accordance 
with the ethical standards of the Partners Human Research Committee, and written informed 
consent was obtained from all participants.
Samples were processed in three separate batches over the course of several years. Because 
measured miRNA expression may be affected by batch effects as well as by other 
nongenetic factors, we first determined potential factors that may need to be accounted for in 
our miR-QTL analysis. For a given factor, we tested for its association with every miRNA 
using a simple linear regression model. We then compared the resulting association P-value 
distribution against the uniform distribution; a uniform P-value distribution would be 
expected if the factor tested does not systematically contribute to the variability of the 
miRNA expression measurements. This procedure identified that 1) sample processing 
batch, 2) surgery year, 3) surgery type, and 4) two qPCR controls are significant contributors 
to the variability of miRNA expression. We therefore corrected for the effects of these 
factors for all miRNAs using mixed-effect modeling37 and retained the fitted residuals for 
miR-QTL analysis. The model we used, expressed using R/lme4 notation, is
where E is the measured expression; here we treat batch, surgery year, and surgery type as 
random effects and the two control probes (X1 and X2) as fixed effects.
Genotyped SNPs were initially filtered to have a minor allele frequency (MAF) >0.01, SNP 
call rate >95%, individual missing rate <1%, and Hardy-Weinberg equilibrium (HWE) test P 
>1e-6. SNPs were then imputed using MaCH-Admix38 with 1000 Genomes haplotype data 
(Phase I release version 3) as reference. Imputed SNPs were filtered based on imputation 
quality (Rsq >0.3). After imputation, the combined genotyped and imputed SNPs were 
filtered again to ensure MAF >0.03, SNP call rate >95%, individual missing rate <1%, and 
HWE P >1e-6.
To reduce the potentially confounding effect of race, only Caucasian patients’ samples were 
selected for analysis by excluding the small number of non-Caucasians. Furthermore, to 
account for population stratification, we computed principal components of SNP genotypes 
using Eigenstrat39 and included them in our association model (see below). A total of 424 
samples were used to perform miR-QTL analysis.
We performed association between each of the four miRNAs and the SNPs located within 1 
Mb on either side of the transcription start site of the miRNAs using a linear, additive model. 
We included the first 3 principal components of SNP genotypes as covariates in the miR-
QTL analysis. Gender, age, and pre-surgery BMI were also included as covariates. The 
“Matrix eQTL” package40 was used to perform the association analysis in R. The “dosage” 
output (.dose files) from MaCH-Admix was used for association analysis.
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Bone marrow-derived macrophage (BMDM) culture and Ago2 PAR-CLIP analysis
Mice were euthanized using carbon dioxide, and bone marrow cells from the femur and tibia 
were collected by flushing through a 23-gauge needle with PBS. Bone marrow cells were 
cultured with complete growth media containing DMEM and 20% L929 cell conditioned 
medium for 6 d (ref. 41),
BMDM for the PAR-CLIP experiment were incubated with 100 μM 4-thio-uridine (Sigma) 
for 16 h, washed with PBS and UV-crosslinked (0.15 J/cm2 total energy using 365 nm UV 
light in a Stratalinker (Invitrogen)). BMDM were then harvested and frozen at −80 °C. The 
details of the PAR-CLIP protocol were described previously42,43 with several minor 
modifications as follows. We used mouse monoclonal anti-mouse AGO2 antibody (Clone 
2D4 WAKO) for Ago2 IP. Immunoprecipitated RNA-protein complex was labeled with γ-
[32P]-ATP and polynucleotide kinase, purified by PAGE and the cDNA library was prepared 
for deep sequencing. We used 3′ adapters, 5′ adapters, RT primers, and PCR primers from 
the Illumina TruSeq Small RNA Sample Preparation Kit. PAR-CLIP small RNA libraries 
from 2 samples were sequenced for 45 cycles on the Illumina HiSeq 2000 platform 
(Illumina).
We used PARalyzer software to identify miRNA binding sites, as described previously44. 
Briefly, reads were aligned to the mouse genome sequence, version MM9. Ago2 PAR-CLIP 
clusters were defined as having at least 25 reads, as excluding genomic repeat regions, and 
as meeting the T to C conversion criteria. We only considered overlapping sequence reads 
that exceeded a threshold of ≥ 50% T to C conversion frequency. We selected sites with 
more than 100 reads for further analysis, such as miRNA prediction. Clusters that 
overlapped with predicted miRNA binding sites from the TargetScan database (TargetScan 
6.2, mouse non-conserved and conserved predictions) were identified using custom scripts. 
Since TargetScan 6.2 uses canonical seed match sites (≥7mer1A, i.e., nucleotide 2–7 match 
with an A across from position one of the mature miRNA), when no TargetScan 6.2 
predictions were found for a given cluster, we also used the PITA algorithm (Segal Lab of 
Computational Biology) to search for miRNA target sites; this algorithm allows either 1 G:U 
wobble or 1 mismatch in the 7–8 nt seed site. Detailed information on PAR-CLIP data, 
miRNA sequencing data and mRNA sequencing data were published previously29, and 
sequencing data have been submitted to the GEO database with the following accession 
number: GSE63199.
Hepatic miRNA expression in mice and rhesus macaques fed chow versus high-fat diets
Male rhesus monkeys (age 7–13 years old) were fed a standard (TestDiet no. 5038; Purina 
Mills) or high-fat, high-sucrose diet (42% kcal in fat, Custom formula no. 07802; Harlan, 
Teklad, Madison, WI) for 2 years and maintained as previously described45. Animal 
procedures were approved by the Animal Care and Use Committee of the National Institute 
on Aging (NIA) Intramural Research Program. After animal euthanasia, liver RNA was 
isolated using the Bullet Blender Homogenizer (Next Advance) in TRIzol. For miRNA 
quantification, 1 μg of total RNA was reverse transcribed using the miScript II RT Kit 
(Qiagen). Primers specific for miR-128-1, miR-148a, miR-130b and miR-301b (Qiagen) 
were used and values were normalized to SNORD68 (Qiagen) as a housekeeping gene.
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Male C57BL/6J mice were purchased from the Jackson Laboratories (Bar Harbor, ME) and 
kept under constant temperature and humidity in a 12 h controlled dark/light cycle. For HFD 
studies, 8-week old male mice were placed on a chow diet or HFD containing 0.3% 
cholesterol and 21% (wt/wt) fat (Dyets, Inc.) for 3 weeks. Liver samples were collected as 
previously described46 and stored at −80 °C until total RNA was harvested for miRNA 
expression analysis, as described above.
Mouse peritoneal macrophage miRNA antisense treatment and cholesterol efflux
Thioglycollate-elicited peritoneal mouse macrophages (1 × 106 cells per well) were 
transfected either with a control inhibitor (IN-001005-01-20, Dharmacon) or an anti-miRNA 
inhibitor (#Inh-mmu-miR-128-3p: #IH-310398-08-0005, Inh-mmu-miR-148a-3p: 
#IH-310496-07-0005, Inh-mmu-miR-130a-3p: #IH-310399-07-0005, Inh-mmu-
miR-301a-3p: #IH-310482-07-0005, Dharmacon) 48 h before loading with 0.5 μCi/ml 3H-
cholesterol for 24 h with or without the LXR agonist T0901317 (Sigma-Aldrich; 3 μmol/l) 
for 12 h. Then, cells were washed twice with PBS and incubated in RPMI supplemented 
with 2 mg/ml fatty-acid free BSA (FAFA-media) in the presence of ACAT inhibitor (Sandoz 
58-035, Sigma-Aldrich; 2 μmol/l) for 2 h before addition of 50 μg/ml human ApoA1 in 
FAFA-media with or without the indicated treatments. Supernatants were collected after 6 h 
and expressed as a percentage of total cell 3H-cholesterol content (total effluxed 3H-
cholesterol + cell-associated 3H-cholesterol).
Quantitative RT-PCR
Total RNA and miRNA were extracted from cells using TRIzol (Life Technologies/
Invitrogen) and the mirVana miRNA Isolation Kit (Life Technologies/Invitrogen), 
respectively, according to the manufacturer’s instructions. After extraction, total RNA and 
miRNA were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
and the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies/Invitrogen). RT 
products were quantified by real-time qPCR (Lightcycler, Roche) using the TaqMan 
Universal PCR Master Mix. The amount of the indicated mRNA or miRNA was normalized 
to the amount of GAPDH mRNA and U6 RNA, respectively. Total RNA for miRNA 
expression levels analysis in human tissues was purchased from Ambion (FirstChoice 
Human Total RNA Survey Panel, AM6000). To quantify pri-miRNA-128-1 levels, RNAs 
were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit and 
quantified with the specific TaqMan Pri-miRNA assay for pri-miRNA-128-1 (Life 
Technologies/Invitrogen). To quantify miR-148a, miR-130b and miR-301b levels, RNAs 
were reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit and 
quantified with the miRNA-specific TaqMan miRNA assays (Life Technologies/Invitrogen). 
PCR primer sequences are available from A.M.N. upon request.
Antibodies
Rabbit anti-LDLR (ab30532), mouse anti-ABCA1 (ab18180), rabbit anti-AMPKα1 
(ab32047), rabbit anti-AMPKα2 (ab3760), rabbit anti-INSIG1 (ab-70784), rabbit anti-
CPT1α (ab83862), and mouse anti-Sik1 (ab64428) were purchased from Abcam Research 
Products, Cambridge, UK. Mouse anti-β tubulin (T7816) was purchased from Sigma 
Aldrich. Rabbit anti-SIRT1 (CY-P1016) was purchased from Cyclex. Rabbit anti-IRS1 
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(2382) was purchased from Cell Signaling Technology. Rabbit anti-IR (sc-711) was 
purchased from Santa Cruz Biotechnology. Rabbit anti-AKT (9272) and rabbit anti-
phospho-AKT (9271) were purchased from Cell Signaling, mouse anti-PGC1α 
(ST1202-1SET) from Millipore, and mouse anti-HSP90 (no. 610418) from BD Bioscience.
Plasmids, miRNA antisense and precursor oligonucleotide transfection
Luciferase plasmids harboring the ABCA1 (HmiT004727) and LDLR (HmiT010577) 3′ 
UTRs were purchased from GeneCopoeia. Mutagenesis of the 3′ UTRs was performed with 
the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) according to the 
manufacturer’s instructions. Primer sequences used to mutate the three miR-128-1 binding 
sites in the LDLR 3′ UTR are the following (all are in 5′–3′ order): (816; 867): 
CACTTTCTCAGTTCAGAGTTG TACCCTATGTACATTTGGCATTTGTGTTATT; (2046; 
2078): GTCCCCAGG GACAAAACCCTATGTCCCCCCCAG; (2444; 2506): 
TAGAAGGTTTTTGTA 
GCCTGAATGTCTTATTGTTATCAATTAAATTTCTTAAATGAACCAATT. The two 
binding sites in the ABCA1 3′ UTRs were mutated with the following primers: (2255; 
2329): CAAGGCCATATTTTAAAAAATCAAAAGGCAATGT 
AAACTATTTTGAAGAAAACACAACATTTTAA; (2563; 2626): TTTGGGAC 
ACCTCAGAAAACTTATTAACAAATGTAAATATGAGAAATACAGAAGAA AATAATA. 
Mutagenesis of the two miR-148a binding sites in the LDLR 3′ UTR were performed with 
the following primers: (840; 893): ACTGTGTACATTTG 
GCATTTGTGTTATTATTTTACAATGTTTTCTGTCGTGTGT; (2547; 2587): 
GAAATCGCCGTGTTACTGTTACAATGATGTCCGGAGAGACA. The four miR-130b 
and miR-301b binding sites in the LDLR 3′ UTR were mutated using the following 
primers: (796; 836): CCATTCCCGTGGTCTCCTTACCCTTT CTCAGTTCAGAGTTG; 
(841;892): CTGTGTACATTTGGCATTTGTGTTA 
TTATTTTACCCTGTTTTCTGTCGTGTG; (1948; 1987): TTCTGAAATCG 
CCGTGTTACTGTTACCCTGATGTCCGGAG; (2136; 2192): AGATAGTGG 
GGATTTTTTGTTATGTTTACCCTTTGTATATTGGTTGAAACTGTTATC. Mutagenesis 
of both the miR-128-1 and miR-130b/miR-301b binding sites in the ABCA1 3′ UTR was 
performed using a single primer (the two binding sites for these three miRNAs overlap): 
(3081; 3131): CTTTACGCTGTCTGTAATG 
GGATCTATTTTTACAATGGAATATCTGAGAAT. The mutated residues are indicated in 
bold. Antisense (no. 4464084) and precursor (no. 4464066) oligo-nucleotides for 
miR-128-1, miR-148a, miR-130b and miR-301b for cell culture studies were purchased 
from Life Technologies/Invitrogen.
Cell culture transfection
HepG2, J774A.1 and HEK293T cells were obtained from the ATCC and propagated 
according to ATCC’s instructions. Transfection of antisense and precursor oligonucleotides 
(35 nM final concentration) were performed in HepG2 cells using Lipofectamine 
RNAiMAX Reagent (Life Technologies/Invitrogen), and in J774A.1 cells using TransIT 
TKO Transfection Reagent (Mirus Bio LLC) according to the manufacturers’ instructions. 
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Plasmid transfection in HEK293T cells was performed with Lipofectamine 2000 (Life 
Technologies/Invitrogen) according to the manufacturer’s instructions.
Luciferase assays and immunoblotting
Luciferase activity was measured according to the manufacturer’s protocol (Promega, 
Madison, WI) and was normalized to β-galactosidase activity. Immunoblotting was 
performed by standard procedures.
Efflux of cholesterol from mouse J774A.1 macrophages
J774A.1 mouse macrophage cells were seeded in 24-well plates at 2 × 105 cells per well. 
After 24 h, cells were incubated in 3H-cholesterol and transfected with antisense or 
precursor oligonucleotides for 24 h. Then, cells were washed twice with PBS and incubated 
with fresh 5% lipoprotein deficient bovine calf serum (BT-907, Biomedical Technology) and 
ApoA1 protein (BT 927, Biomedical Technology) at 25 μg/ml final concentration. After 2 
h, 3H-cholesterol present in medium and in alkaline lysed cells was determined by liquid 
scintillation counting.
Dil-LDL binding
HepG2 cells were transfected in 12-well plates at 5 × 105 cells/well. 24 h after antisense or 
precursor oligonucleotide transfection, Dil-LDL labeling procedure was performed 
according to the manufacturer’s protocol (BT-904, Biomedical Technology).
Intra-peritoneal glucose tolerance test and insulin tolerance test
Experiments were performed in 8 week-old Apoe null male mice purchased from Jackson 
Laboratory and treated once-weekly by subcutaneous injection with an LNA antimiR-128-1 
(20 mg/kg) over 16 weeks. Mice were fed a Western-type diet supplemented with 45% kcal 
from milk fat (D12451, Research Diets) during the treatment. IP-GTT was performed in 
mice fasted for 6 h. Mice were injected with 1.5 mg/g D-(+)-glucose (G7528, Sigma 
Aldrich). Glucose levels were measured at 0 (before injection), 30, 60 and 120 min post-
injection. Insulin tolerance test (ITT) was performed in 4 h fasted mice. Mice were injected 
with 0.00075 U/g insulin (I9278-5 ML, Sigma Aldrich). Glucose levels were measured at 0 
(before injection), 15, 45 and 60 min after injection.
Lipid extraction from liver tissue
Each mouse liver was homogenized and incubated in a hexane:isopropanol (3:2) mixture for 
16 h. After centrifugation at 3,000g for 10 min at 4 °C, the organic phase with lipids was 
removed and the pellet was used for protein quantification using the Bradford assay. To 
quantify the levels of triglycerides and cholesterol in the organic fraction, solvents in the 
lipid extract were removed under vacuum for 30 min and the remaining lipids were 
dissolved in DMSO. Colorimetric assays to measure triglycerides and cholesterol were 
performed according to the manufacturer’s instructions (Wako diagnostics). Lipid levels 
were normalized to protein concentrations and expressed as μg of lipid/mg of protein.
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Liver histology
Liver tissue from each study animal was sectioned for histology47,48. Frozen and paraffin-
embedded sections were prepared for staining for fat content with Oil Red O and H&E, 
respectively. Metamorph NX software (Molecular Devices, Sunnyvale, CA) was used to 
calculate the percent Oil Red O staining from digital images obtained at 20 × magnification. 
A paired t-test was used to compare the percentage of Oil Red O staining in the control LNA 
versus antimiR-128-1–treated mice. H&E slides were assigned an ordinal value on the basis 
of the amount of macrovesicular and microvesicular steatosis identified in a representative 
20× image: 0, none; 1, <10%; 2, 10–30%; 3, >30%.
Statistics
In vitro experiments were repeated at least three times and histograms represent mean ± s.d. 
The number of animals used in each mouse study was determined on the basis of pertinent 
literature for comparable studies in which the desired effect sizes were admitted to be 
significant. No mice were excluded in the analyses. Data analyses from mouse experiments 
show mean ± s.e.m. The scoring of liver steatosis was performed in a blinded manner. The 
area under the curve (AUC) was calculated using the linear trapezoidal method based on a 
linear interpolation between data points49. The AUC was calculated as follows: AUC = 1/2 
(C1+C2), where C indicates the concentration of lipids in two incremental FPLC fractions. 
The average AUC value for the VLDL, LDL or HDL fractions was calculated and indicated 
with the s.e.m. and P value. Statistical differences were measured using an unpaired two-
sided Student’s t-test. P ≤ 0.05 was considered as statistically significant. Data analysis was 
performed using Excel Software Version 14.4.5. Statistical tests for miR-QTL and liver 
steatosis analyses are indicated in the corresponding Online Methods sections.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Identification of miRNAs located in genomic loci that are enriched for SNPs associated with 
abnormal circulating total cholesterol, triglyceride, LDL-C and HDL-C levels. (a–c) Locus 
plots showing associations from Willer et al.11 with total cholesterol (TC), triglycerides 
(TG), LDL-C (LDL) and HDL-C (HDL) at the regions harboring miR-128-1 (a), miR-148a 
(b), and miR-130b and miR-301b (c). Color saturation levels correspond to linkage 
disequilibrium values (R2) to the top SNP for that particular trait in the 1000 genome EUR 
panel. Genetic recombination rates, estimated from the 1000 Genomes sequencing project, 
are plotted in blue. (d,e) Regional association plots for the eQTL analysis (top track) aligned 
against the Willer et al.11 joint GWAS analysis (middle track) for total cholesterol (TC) for 
miR-128-1 (d) and LDL cholesterol for miR-148a (e). Green arrows (bottom track) 
represent miRNA and protein-coding transcripts as annotated by the GENCODE Project. hsa 
refers to human (Homo sapiens) miRNA. The data show concordance of SNP peaks and 
eQTL signals, linking miR-128-1 and miR-148a hepatic expression to SNPs associated with 
abnormal circulating cholesterol levels.
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Figure 2. 
Expression of LDLR and ABCA1 is regulated by miRNAs located in genomic loci 
associated with abnormal circulating blood lipid levels. (a–d) Immunoblots of predicted 
targets of miR-128-1 (a), miR-148a (b), miR-130b (c) and miR-301b (d) that are involved in 
cholesterol and lipid regulation (LDLR and ABCA1) and energy homeostasis (insulin 
receptor (InsR) precursor (Pre) and mature (Beta) forms, IRS1, INSIG1, SIRT1, AMPK-α1, 
AMPK-α2, SIK1, CPT1-α, PGC1-α). Human HepG2 hepatoma cells were transfected with 
the indicated precursor (pre-miRNA) or antisense (antimiR) oligonucleotides. β-tubulin was 
used as a loading control. (e) Luciferase activity in HEK293T cells transfected with a 
luciferase reporter with or without the LDLR 3′ UTR. (f) Luciferase activity in cells co-
transfected with the indicated miRNA precursor and a wild-type LDLR 3′ UTR-luciferase 
reporter or a reporter harboring point mutations in the predicted miRNA target sites. (g,h) 
Uptake of Dil-LDL by human HepG2 hepatoma cells after treatment with miR-128-1, 
miR-148a, miR-130b, or miR-301b precursors (g) or antimiRs (h). (i,j) Cholesterol efflux 
from HepG2 cells loaded with radiolabeled cholesterol after transfection with the indicated 
precursors (i) or antimiRs (j). PC, precursor control. AC, antimiR control. a.u., arbitrary 
units. All errors bars represent mean ± s.d. of ≥3 experiments in triplicate. Statistical 
significance between groups is calculated by unpaired t-test, *P < 0.05, **P < 0.01, ***P < 
0.001 compared to cells transfected with empty vector (e), PC (f,g,i) or AC (h,j).
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Figure 3. 
miR-128-1, miR-148a, miR-130b and miR-301b regulate ABCA1 expression and 
cholesterol efflux in mouse macrophages. (a) Luciferase activity in HEK293T cells 
transfected with a luciferase reporter with or without the ABCA1 3′ UTR. (b) Luciferase 
activity in cells co-transfected with the indicated miRNA precursor and a wild-type ABCA1 
3′ UTR-luciferase reporter or a reporter harboring point mutations in the predicted miRNA 
target sites. (c) Abca1 expression in the mouse macrophage cell line J774A.1 after 
overexpression (pre-miRNAs) or inhibition (antimiRs) of miR-128-1, miR-148a, miR-130b 
or miR-301b. β-tubulin was used as a loading control. (d) Cholesterol efflux from J774A.1 
cells loaded with radiolabeled cholesterol after transfection with the indicated precursors 
(left) and antimiRs (right). (e) Abca1 expression in LXR agonist (T0901317; T090)-
stimulated mouse peritoneal macrophages transfected with the indicated antimiRs. A 
scrambled antimiR was used as a control. Hsp90 was used as a loading control. (f) 
Cholesterol efflux from mouse peritoneal macrophages after transfection of the indicated 
antimiRs (inh-miRNAs) with or without T0901317 treatment. Cl, scrambled antimiR 
control. (g) Ago2 PAR-CLIP analysis of mouse BMDM. Genome browser screen shot 
(mouse mm9 release) of the Abca1 locus is shown. Black shadings on the top line show 
RNA-seq data (RPKM, reads per kilobase per million mapped reads) from BMDM. Ago2 
PAR-CLIP reads, shown in blue, identified five distinct, high-confidence miRNA binding 
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sites. The Abca1 transcript is indicated by blue boxes (the wider box indicates the coding 
region and the narrower box indicates the 3′ UTR) and the arrows indicate the direction of 
transcription of the Abca1 gene. RefSeq, reference sequence database. TargetScan 6.2 was 
used to identify miRNAs that interact with the miRNA binding sites identified by the Ago2 
PAR-CLIP analysis. miRNAs identified in this study are labeled in red. MicroRNA 
expression levels in mouse BMDM are indicated in colored boxes on a log10 scale (red 
indicates high expression, black indicates low expression). PC, Precursor control. AC, 
AntimiR control. a.u., arbitrary units. All errors bars represent mean ± s.d. of ≥3 
experiments in triplicate. Statistical significance between groups is calculated by unpaired t-
test, *P < 0.05, **P < 0.01 compared to cells transfected with the empty vector (a), PC (b,d) 
or AC (d,f).
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Figure 4. 
Overexpression of miR-128-1 and miR-148a in C57BL/6J mice decreases circulating levels 
of HDL-C, whereas antisense antagonism of these miRNAs increases LDL-C clearance. (a) 
Analysis of hepatic Ldlr and Abca1 expression in mice injected with lentivirus expressing 
miR-128-1 or miR-148a (n = 7 per group). β-tubulin was used as a loading control. (b) Fast 
protein liquid chromatography (FPLC) analysis of pooled sera from C57BL/6J mice (n = 10) 
injected with lentivirus expressing miR-128-1 or miR-148a and fed HFD. Control mice were 
injected with a control lentivirus expressing a scrambled pre-miRNA. (c) Mean area under 
the curve (AUC) values calculated for HDL-C fractions 33–38 isolated by FPLC from b. (d) 
Copepod green fluorescent protein (copGFP) expression in the liver of C57BL/6J mice 
infected with lentiviruses, which encoded the indicated pre-miRNA together with copGFP. 
(e–h). Hepatic expression of Abca1 (e), Ldlr (f), Irs1 (g), and Cpt1a (h) in C57BL/6J mice 
fed HFD and overexpressing the indicated miRNAs. n = 10 mice per group. (i,j) LDL 
clearance after inhibition of miR-128-1 (i) or miR-148a (j) in C57BL/6J mice (n = 5 per 
group). Control mice were injected with a scrambled LNA. Error bars represent s.e.m. 
Statistical significance between groups is calculated by unpaired t-test, *P < 0.05, **P < 
0.01, ***P < 0.001 compared to mice injected with a control lentivirus (b,c,e–h) or a 
scrambled LNA control (i,j). a.u., arbitrary units.
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Figure 5. 
Antisense inhibition of miR-148a in Apoe−/− mice fed a Western-type diet results in altered 
circulating lipoprotein/lipid levels. (a) Hepatic miR-148a levels determined by qRT-PCR in 
Apoe−/− mice injected with a LNA targeting miR-148a (n = 10 per group). (b) Ldlr and 
Abca1 expression in liver from Apoe−/− mice treated with antimiR-148a. (c) Hepatic 
expression of Ldlr, Abca1, and Cpt1a mRNA after short-term (5 d) antimiR-148a treatment 
of Apoe−/− mice fed a Western-type diet (n = 10 mice per group). (d) FPLC analysis of 
pooled sera from Apoe−/− mice (n = 10) fed a Western-type diet after treatment with 
antimiR-148a for 5 d. (e,f) Mean AUC values calculated for the LDL (e) and HDL (f) 
fractions (17 to 24 and 31 to 37, respectively) isolated by FPLC from d. (g) FPLC analysis 
of pooled sera from 10 mice after longitudinal (16 weeks) antimiR-148a treatment of 
Apoe−/− mice fed a Western-type diet. (h,i) Mean AUC values calculated for the 
VLDL/LDL (h) and HDL (i) fractions (15 to 24 and 31 to 36, respectively) isolated by 
FPLC from g. Control mice were injected with a scrambled LNA. AUC, area under the 
curve. Error bars represent s.e.m. Statistical significance between groups is calculated by 
unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary units.
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Figure 6. 
Antisense inhibition of miR-128-1 in Apoe−/− mice fed a Western-type diet results in altered 
circulating lipoprotein/lipid levels, improved glucose homeostasis/insulin signaling and 
decreased hepatic steatosis. (a) Hepatic miR-128-1 levels determined by quantitative RT-
PCR in Apoe−/− mice injected with an LNA targeting miR-128-1. n = 10 per group. (b) 
Immunoblots in liver tissue from Apoe−/− mice treated with antimiR-128-1 showing 
expression levels of Ldlr, insulin receptor (InsR) precursor (Pre) and mature (Beta) forms, 
Irs1, phosphorylated (activated) and total Akt1. β-tubulin was used as a loading control. 
(c,d) Levels of cholesterol (c) and TAGs in the VLDL fraction (d) isolated by FPLC 
fractionation from pooled sera of Apoe−/− mice (n = 10) fed a Western-type diet. Histograms 
represent the mean AUC values for cholesterol (c, right) and triglyceride (d, right). (e) H&E 
staining (left) and steatosis quantification (right) in liver of Apoe−/− mice treated with 
antimiR-128-1 over 16 weeks. Micrographs from two control LNA–treated (#1 and #2) and 
two antimiR-128-1 LNA–treated (#3 and #4) mice are shown. Scale bars, 1 mm. (f) IP-GTT 
performed after 16 weeks of treatment with antimiR-128-1 in Apoe−/− mice (n = 10 per 
group). (g) VLDL-TAG secretion in Apoe−/− mice treated with antimiR-128-1 after 
inhibition of lipoprotein lipase with Triton WR1339 (n = 10 per group). Error bars represent 
s.e.m. Statistical significance between groups is calculated by unpaired t-test, *P < 0.05, **P 
< 0.01, ***P < 0.001. a.u., arbitrary units.
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